194 related articles for article (PubMed ID: 33349137)
1. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
2. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
[TBL] [Abstract][Full Text] [Related]
3. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
[TBL] [Abstract][Full Text] [Related]
4. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
6. Extrapolation of Survival Curves from Cancer Trials Using External Information.
Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ
Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
8. The current application of the Royston-Parmar model for prognostic modeling in health research: a scoping review.
Ng R; Kornas K; Sutradhar R; Wodchis WP; Rosella LC
Diagn Progn Res; 2018; 2():4. PubMed ID: 31093554
[TBL] [Abstract][Full Text] [Related]
9. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
[TBL] [Abstract][Full Text] [Related]
10. Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses.
Cislo PR; Emir B; Cabrera J; Li B; Alemayehu D
Value Health; 2021 Nov; 24(11):1643-1650. PubMed ID: 34711365
[TBL] [Abstract][Full Text] [Related]
11. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.
Mozumder SI; Rutherford MJ; Lambert PC
BMC Med Res Methodol; 2021 Mar; 21(1):52. PubMed ID: 33706711
[TBL] [Abstract][Full Text] [Related]
12. Regression models for interval censored data using parametric pseudo-observations.
Johansen MN; Lundbye-Christensen S; Larsen JM; Parner ET
BMC Med Res Methodol; 2021 Feb; 21(1):36. PubMed ID: 33588771
[TBL] [Abstract][Full Text] [Related]
13. How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
Kearns B; Stevens J; Ren S; Brennan A
Pharmacoeconomics; 2020 Feb; 38(2):193-204. PubMed ID: 31761997
[TBL] [Abstract][Full Text] [Related]
14. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
15. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?
Cooper M; Smith S; Williams T; Aguiar-Ibáñez R
J Med Econ; 2022; 25(1):260-273. PubMed ID: 35060433
[TBL] [Abstract][Full Text] [Related]
16. survextrap: a package for flexible and transparent survival extrapolation.
Jackson CH
BMC Med Res Methodol; 2023 Nov; 23(1):282. PubMed ID: 38030986
[TBL] [Abstract][Full Text] [Related]
17. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
Gallacher D; Kimani P; Stallard N
Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different parametric proportional hazards models for interval-censored data: a simulation study.
Gong Q; Fang L
Contemp Clin Trials; 2013 Sep; 36(1):276-83. PubMed ID: 23916917
[TBL] [Abstract][Full Text] [Related]
19. An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.
Vickers A
Med Decis Making; 2019 Nov; 39(8):926-938. PubMed ID: 31631772
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]